Tourmaline Bio (NASDAQ:TRML – Get Free Report) and X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.
Profitability
This table compares Tourmaline Bio and X4 Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tourmaline Bio | N/A | -20.97% | -20.56% |
| X4 Pharmaceuticals | N/A | -236.19% | -75.14% |
Institutional and Insider Ownership
91.9% of Tourmaline Bio shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 11.0% of Tourmaline Bio shares are held by insiders. Comparatively, 1.6% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tourmaline Bio | N/A | N/A | -$42.12 million | ($2.82) | -4.59 |
| X4 Pharmaceuticals | $1.12 million | 61.76 | -$101.17 million | ($0.09) | -4.52 |
Tourmaline Bio has higher earnings, but lower revenue than X4 Pharmaceuticals. Tourmaline Bio is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Tourmaline Bio has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.12, meaning that its stock price is 88% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for Tourmaline Bio and X4 Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tourmaline Bio | 0 | 0 | 7 | 0 | 3.00 |
| X4 Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
Tourmaline Bio currently has a consensus target price of $54.67, indicating a potential upside of 322.46%. X4 Pharmaceuticals has a consensus target price of $3.50, indicating a potential upside of 760.59%. Given X4 Pharmaceuticals’ higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than Tourmaline Bio.
Summary
Tourmaline Bio beats X4 Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About Tourmaline Bio
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Receive News & Ratings for Tourmaline Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tourmaline Bio and related companies with MarketBeat.com's FREE daily email newsletter.
